U.S. Construction Stock News

OTCPK:FMCC
OTCPK:FMCCDiversified Financial

Will Stronger Q2 2026 Earnings and Mortgage Profitability Change Federal Home Loan Mortgage's (FMCC) Narrative?

In the past quarter, Federal Home Loan Mortgage Corporation (Freddie Mac) reported second-quarter 2026 net income of US$3.84 billion and first-half 2026 net income of US$7.40 billion, both higher than the same periods a year earlier. This step-up in profitability, coming alongside Freddie Mac’s role in supporting U.S. housing finance, highlights how its core mortgage activities are converting into stronger earnings. We’ll now examine how this stronger net income performance affects Freddie...
NYSE:TALO
NYSE:TALOOil and Gas

Talos Energy (TALO) Could Be 17% Undervalued After Its Q2 Guidance Upgrade

Talos Energy (TALO) is back in focus after reporting Q2 2026 results that exceeded its own production guidance and delivered record free cash flow, along with a higher full year production outlook. See our latest analysis for Talos Energy. The recent Q2 2026 update and higher production outlook appear to have supported sentiment in Talos Energy, with a year to date share price return of 38.4% and a 1 year total shareholder return of 92.94% indicating strong momentum despite a softer 3 year...
NYSE:MGM
NYSE:MGMHospitality

MGM Resorts (MGM) Stock Could Be Cheap On Cash Flow Yet Pricey On Earnings

MGM Resorts International stock has returned 24.7% over the past year, yet its valuation checks send mixed signals as a Discounted Cash Flow (DCF) intrinsic value estimate points to upside while earnings-based multiples lean the other way. Over the last 12 months, the 24.7% gain suggests the market has become more positive on MGM Resorts International, so fresh buyers now face a higher entry point than a year ago. The ongoing go-private proposal from People Incorporated can support...
NYSE:ADT
NYSE:ADTConsumer Services

ADT (ADT) Stock Looks Reasonable Despite An Earnings Discount

ADT stock has had a mixed run, with the share price up 26.9% over the past three years while shorter term returns have been weaker, and the current valuation checks do not point to a clear bargain or clear overpricing. With recent headlines split between product progress and a large scale data breach, investors are trying to work out how much of ADT's risk and opportunity set is already reflected in the current price around US$7.45. ADT has delivered a 26.9% return over three years, which...
NasdaqGM:FLY
NasdaqGM:FLYAerospace & Defense

Does Firefly Aerospace (FLY) Have A Bigger Defense Role After Its $93.7 Million Win?

Firefly Aerospace (NasdaqGM:FLY) subsidiary SciTec has secured a US$93.7 million U.S. Space Force contract to modernize ground-based radar infrastructure. The award focuses on digital upgrades to radar systems that support U.S. national security programs. The contract marks a significant step for Firefly’s government services business within defense technology. For investors tracking how defense, space and AI heavy infrastructure are coming together, this contract sits within a broader...
NYSE:ATR
NYSE:ATRPackaging

The Bull Case For AptarGroup (ATR) Could Change Following Rising Sales, Softer EPS And Buybacks

AptarGroup, Inc. recently reported past second-quarter 2026 results, with sales rising to US$1,026.51 million while net income fell to US$87.57 million, and also posted lower basic and diluted earnings per share from continuing operations compared with a year earlier. Alongside this, the company completed a US$149.97 million share repurchase covering 1,110,496 shares, highlighting active capital returns even as earnings softened. Next, we’ll examine how higher sales but lower earnings,...
NasdaqGS:ADUS
NasdaqGS:ADUSHealthcare

Why Did Addus HomeCare (ADUS) Move Today?

Why this leadership change at Addus HomeCare matters for investors Addus HomeCare (ADUS) has drawn fresh attention after announcing that President and Chief Operating Officer Heather Dixon is no longer with the company. Former executive Brad Bickham is returning as interim COO for one year. This type of leadership shift can focus investors on how stable they believe the company’s direction is. It can also raise questions about how closely future decisions will align with the approach that...
NYSE:ARES
NYSE:ARESCapital Markets

Is Ares Management (ARES) Reasonable Or Stretched After Record Fundraising?

Ares Management has delivered a 131.2% gain over the past 5 years, yet the current valuation checks point to the stock trading at a premium to its intrinsic value estimate. The Excess Returns model and market multiple signals both indicate that Ares Management is pricing in strong expectations after a period of solid long term performance. Over the past 5 years, Ares Management has returned 131.2%, which means long term holders have already seen a substantial payoff from owning the...
NYSE:FOUR
NYSE:FOURDiversified Financial

Shift4 Payments (FOUR) Could Be 26% Undervalued On Cut Guidance

Shift4 Payments (FOUR) drew fresh attention after reporting second quarter 2026 results that combined higher sales with lower earnings, along with a reduction in full year guidance linked to Middle East travel disruption and currency pressures. See our latest analysis for Shift4 Payments. That reset in guidance has fed directly into the share price, which closed at US$41.04 after a 1 day share price return that declined 4.91%, a 7 day share price return that declined 26.20%, and a 1 year...
NasdaqGS:PODD
NasdaqGS:PODDMedical Equipment

Insulet (PODD) Could Be 39% Undervalued After Strong Earnings And Higher 2026 Outlook

Why Insulet’s latest earnings and outlook matter for investors Insulet (PODD) recently reported second quarter 2026 results that showed higher sales, revenue and net income compared with a year earlier, alongside stronger earnings per share from continuing operations. The company also issued new guidance that points to total GAAP revenue growth expectations in the high teens for the upcoming quarter and just above 20% for the full 2026 year. See our latest analysis for Insulet. Despite the...
NYSE:GWW
NYSE:GWWTrade Distributors

Grainger (GWW) Stock Could Be 12% Above Fair Value Following Q2 Outlook Raise

W.W. Grainger stock has delivered a very strong 5 year run, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and the earnings multiple checks currently point to the shares trading at a premium rather than as a clear bargain. W.W. Grainger has returned 213.8% over 5 years, which puts extra focus on whether the current price still gives investors enough compensation for risk. Recent strong results and an increased outlook can support high expectations for revenue and earnings...
NasdaqGS:INCY
NasdaqGS:INCYBiotechs

Incyte (INCY), What Is Behind The Latest Attention?

Incyte (INCY) is in focus after the European Commission approved Opzelura cream for adults with moderate atopic dermatitis who are not well served by existing topical therapies. This new indication broadens Opzelura’s approved uses in Europe. See our latest analysis for Incyte. Incyte’s regulatory win comes after a period of firm positive momentum. The share price delivered a 22.52% 90 day share price return and a 48.35% 1 year total shareholder return from a US$121.07 starting point. If you...
NYSE:SSB
NYSE:SSBBanks

SouthState Bank (SSB) Stock Still Looks Below Fair Value On Returns And Earnings

SouthState Bank stock has delivered a strong 77.2% return over the past five years, yet on current checks it still screens as undervalued based on both an Excess Returns intrinsic value estimate and market multiples. For investors, that mix raises the question of whether the current price already reflects the good news or if there is still a margin between market price and intrinsic value. Over the last five years, SouthState Bank has returned 77.2%, which is a solid payoff for shareholders...
NasdaqGS:RPRX
NasdaqGS:RPRXPharmaceuticals

Royalty Pharma (RPRX) Following Mixed Earnings Still Looks Close To Fair Value

Royalty Pharma earnings highlight mixed quarterly picture Royalty Pharma (RPRX) reported second quarter 2026 results with revenue of US$674.14 million and net income of US$17.88 million. The six-month figures showed higher revenue and net income compared with the same period a year earlier. See our latest analysis for Royalty Pharma. Royalty Pharma's share price has risen strongly with a year to date share price return of 48.71%, while the 1 year total shareholder return of 64.61% points to...
NYSE:PHIN
NYSE:PHINAuto Components

Is PHINIA (PHIN) Using Buybacks and Dividends to Redefine Its Long‑Term Capital Playbook?

PHINIA Inc. recently reported past second-quarter 2026 results showing sales of US$940 million and net income of US$40 million, refined its full-year 2026 outlook to net sales of US$3.57–3.67 billion and net earnings of US$155–180 million, and continued sizable share repurchases alongside a US$0.30 quarterly dividend declaration. Together, these updates underline PHINIA’s focus on balancing shareholder cash returns with earnings growth and potential acquisitions in commercial vehicle,...
NYSE:HPE
NYSE:HPETech

Hewlett Packard Enterprise (HPE) Stock Looks Below Fair Value On Cash Flow But Above Fair Value On Earnings

Hewlett Packard Enterprise stock has delivered very strong 5 year returns, yet the current valuation picture is split, with a Discounted Cash Flow (DCF) intrinsic value suggesting the shares trade at a discount while market based multiples lean the other way. Hewlett Packard Enterprise has returned 319.8% over the past 5 years, which puts extra focus on whether today’s price still leaves room for a reasonable margin of safety. Investor expectations today are heavily influenced by demand for...
NasdaqGS:FAST
NasdaqGS:FASTTrade Distributors

Do Fastenal’s (FAST) Mixed Reactions to Solid Revenue Hint at Limits of Its Digital Strategy?

In the past few days, Fastenal reported quarterly results with earnings per share matching expectations and revenue coming in ahead of forecasts, while analysts maintained a mixed, generally cautious stance with a consensus Hold rating. This combination of solid top-line performance and sharply divided analyst opinions is drawing renewed attention to how Fastenal’s business model may respond to current industrial demand conditions. Next, we’ll examine how Fastenal’s in-line earnings but...
NYSE:GM
NYSE:GMAuto

General Motors (GM) Stock Looks Below Fair Value While Earnings Sit Above Fair Value

General Motors stock has delivered a very strong 176.7% return over the past three years, yet the current valuation checks send mixed messages, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to a discount while market based multiples suggest the shares are not obviously cheap. Over the past three years, General Motors has returned 176.7%, which puts extra focus on whether the recent share price reflects a sustainable earnings and cash flow profile. Recent moves to...
NasdaqGM:VERA
NasdaqGM:VERABiotechs

Is Vera Therapeutics (VERA) Undervalued On FDA Approval For TRUTAKNA?

Vera Therapeutics (VERA) drew investor attention after receiving accelerated FDA approval for TRUTAKNA for adult patients with primary IgA nephropathy at risk of disease progression, alongside releasing its latest quarterly financial results. See our latest analysis for Vera Therapeutics. Despite the recent regulatory progress, Vera Therapeutics’ share price has been under pressure, with a 30 day share price return down 27.88% and a year to date share price return down 37.70%. At the same...
NasdaqGS:ABSI
NasdaqGS:ABSIBiotechs

Absci (ABSI) Could Be 32% Undervalued Following ABS 201 Data And Earnings

Absci stock reaction to ABS-201 trial update and earnings Absci (ABSI) drew fresh attention after releasing interim Phase 1 data for ABS-201 and reporting second quarter results, giving you new information on both its clinical pipeline and current financial profile. See our latest analysis for Absci. Absci’s 1-day share price return of 4.44% and 7-day share price return of 10.97% around the ABS-201 update and earnings sit against a 30-day share price decline of 11.23%, alongside a strong...
NasdaqGS:NCNO
NasdaqGS:NCNOSoftware

nCino (NCNO) Adds AI Mortgage Tools, Is The Stock Still Undervalued?

nCino (NCNO) has drawn fresh attention after introducing Model Context Protocol based AI tools inside its Mortgage Suite, giving lenders conversational interfaces that handle routine administrative and loan officer tasks and potentially reshape workflow efficiency. See our latest analysis for nCino. Against this product launch backdrop, nCino’s 1 month share price return of 12.77% and 3 month share price return of 24.98% sit alongside a year to date share price decline of 22.27% and a 1 year...
NasdaqGS:PLMR
NasdaqGS:PLMRInsurance

Palomar Holdings (PLMR) Stock Looks Fully Priced As Growth Expectations Build

Palomar Holdings has delivered a very strong 144.6% return over the past 3 years, yet the stock now screens as overvalued on earnings-based measures and only earns a mixed overall value score. That combination raises the question of whether recent gains already reflect the key positives in the story. The 144.6% 3 year return suggests the market has rerated Palomar Holdings significantly and may now be pricing in optimistic expectations. Expectations for sustained profitable growth can...
NasdaqGM:PRCT
NasdaqGM:PRCTMedical Equipment

Why PROCEPT BioRobotics (PRCT) Could Be 10% Undervalued On Reaffirmed Guidance

PROCEPT BioRobotics (PRCT) stock is back in focus after the company reported second quarter 2026 results and reaffirmed full year guidance, highlighting higher HYDROS adoption alongside continued net losses. See our latest analysis for PROCEPT BioRobotics. Following the earnings release and reaffirmed guidance, PROCEPT BioRobotics has seen a short burst of optimism, with a 1-day share price return of 5.44% and a 7-day share price return of 25.22%. However, the 90-day share price return is...
NYSE:KO
NYSE:KOBeverage

Coca Cola Stock And 2 Consumer Staples Picks For Defensive Dividend Investors

With rate hike odds slipping, a softer jobs report and real wages falling behind inflation, the market is rethinking how to price reliable income and resilience. That shift can punish fragile business models and reward those that hold up when growth and policy look unsure. This article explains how that backdrop interacts with our Defensive Dividend and Consumer Staples Stocks screener and highlights 3 stocks that appear positively exposed to the latest Fed and inflation twist. The stocks...